{"preliminary_commentary":{"by_channel":{"x_thread":53,"youtube":44,"podcast":18},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03901963\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"AURIGA","nct_id":"NCT03901963","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=auriga-nct03901963. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"AURIGA","arms":[{"description":"Participants will receive 1800 milligram (mg) daratumumab by subcutaneous (SC) injection in combination with lenalidomide (orally) as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.","label":"Daratumumab + Lenalidomide","type":"EXPERIMENTAL"},{"description":"Participants will receive lenalidomide (orally) alone as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.","label":"Lenalidomide","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-05-04","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"enrollment":{"count":200,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Daratumumab","otherNames":["DARZALEX"],"type":"DRUG"},{"name":"Lenalidomide","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-23","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-04-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS)","timeFrame":"From randomization up to 12 months"}],"references":[{"citation":"Badros A, Foster L, Anderson LD Jr, Chaulagain CP, Pettijohn E, Cowan AJ, Costello C, Larson S, Sborov DW, Shain KH, Silbermann R, Shah N, Chung A, Krevvata M, Pei H, Patel S, Khare V, Cortoos A, Carson R, Lin TS, Voorhees P. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood. 2025 Jan 16;145(3):300-310. doi: 10.1182/blood.2024025746.","pmid":"39331724","type":"DERIVED"},{"citation":"Swan D, Henderson R, McEllistrim C, Naicker SD, Quinn J, Cahill MR, Mykytiv V, Lenihan E, Mulvaney E, Nolan M, Parker I, Natoni A, Lynch K, Ryan AE, Szegezdi E, Krawczyk J, Murphy P, O'Dwyer M. CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):847-852. doi: 10.1016/j.clml.2022.07.011. Epub 2022 Jul 21.","pmid":"35985959","type":"DERIVED"}],"start_date":{"date":"2019-04-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant","url":"https://clinicaltrials.gov/study/NCT03901963"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/auriga-nct03901963"}